Pharmaids Pharmaceuticals Ltd
Incorporated in 1989, Pharmaids Pharmaceuticals Ltd operates in research, development, and manufacturing services.
It is undergoing a business transition and aims to build a CRDMO platform.[1]
- Market Cap ₹ 108 Cr.
- Current Price ₹ 30.6
- High / Low ₹ 68.0 / 25.6
- Stock P/E
- Book Value ₹ 15.1
- Dividend Yield 0.00 %
- ROCE -15.5 %
- ROE -23.1 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 33.0%
- Company has a low return on equity of -14.9% over last 3 years.
- Debtor days have increased from 36.2 to 47.5 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 2 | 1 | 0 | 1 | 0 | 9 | 4 | 0 | 0 | 2 | 11 | |
| 2 | 2 | 2 | 1 | 1 | 0 | 8 | 4 | 10 | 6 | 10 | 25 | |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | -10 | -6 | -7 | -14 |
| OPM % | -5% | -21% | -28% | -87% | -20% | 1% | 3% | -21,267% | -310% | -134% | ||
| 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0 | -0 | 0 | -0 | -0 | -0 | 0 | 0 | -10 | -6 | -9 | -14 |
| Tax % | -36% | -7% | -33% | 5% | 20% | -108% | 0% | 0% | -24% | -19% | -15% | -25% |
| -0 | -0 | 0 | -0 | -0 | 0 | 0 | 0 | -8 | -5 | -7 | -10 | |
| EPS in Rs | -0.21 | -1.17 | 0.32 | -1.15 | -0.53 | 0.03 | 0.09 | 0.15 | -3.52 | -1.40 | -2.06 | -2.96 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 4% |
| 3 Years: | % |
| TTM: | 353% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -41% |
| TTM: | -86% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 14% |
| 3 Years: | -10% |
| 1 Year: | -54% |
| Return on Equity | |
|---|---|
| 10 Years: | -15% |
| 5 Years: | -17% |
| 3 Years: | -15% |
| Last Year: | -23% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 10 | 21 | 35 | 35 | 35 |
| Reserves | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | 1 | 36 | 29 | 18 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 40 | 21 | |
| 1 | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 15 | 10 | |
| Total Liabilities | 3 | 2 | 2 | 1 | 9 | 8 | 9 | 11 | 25 | 85 | 119 | 84 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 24 | 8 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 4 | 5 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 53 | 53 | 53 |
| 2 | 2 | 2 | 1 | 8 | 8 | 9 | 11 | 19 | 14 | 38 | 18 | |
| Total Assets | 3 | 2 | 2 | 1 | 9 | 8 | 9 | 11 | 25 | 85 | 119 | 84 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | -0 | -0 | -1 | 0 | -0 | -4 | -3 | -8 | -4 | |
| -0 | -0 | 0 | -0 | 0 | 1 | -0 | 0 | -5 | -73 | -19 | 25 | |
| -0 | 0 | -0 | -0 | -0 | 0 | 0 | 0 | 21 | 66 | 25 | -21 | |
| Net Cash Flow | 0 | -0 | 0 | -0 | -0 | -0 | 0 | 0 | 12 | -10 | -2 | -0 |
| Free Cash Flow | 0 | -0 | 1 | -0 | -0 | -1 | 0 | -0 | -6 | -20 | -17 | 14 |
| CFO/OP | -233% | -6% | -97% | 49% | 91% | 221% | 410% | -200% | 41% | 54% | 106% | 25% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 234 | 232 | 240 | 422 | 580 | 12 | 124 | 0 | 25 | 48 | ||
| Inventory Days | 103 | 91 | 131 | 0 | 0 | 17 | 91 | 0 | 4,198 | 1,774 | 0 | |
| Days Payable | 145 | 138 | 245 | 22 | 236 | 0 | 2,067 | |||||
| Cash Conversion Cycle | 192 | 185 | 126 | 422 | 580 | 6 | -21 | 4,198 | -267 | 48 | ||
| Working Capital Days | 181 | 148 | 161 | 227 | 2,653 | 3 | -18 | 14,600 | -471 | -342 | ||
| ROCE % | -5% | -21% | -24% | -30% | -3% | -5% | 1% | 2% | -64% | -11% | -7% | -16% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Number of Subsidiaries count |
|
||||||||
| Number of Permanent Employees count |
|||||||||
| Consolidated Revenue Mix - Job Work % of consolidated revenue |
|||||||||
| Consolidated Revenue Mix - Sale of Products % of consolidated revenue |
|||||||||
| Consolidated Revenue Mix - Sale of Services % of consolidated revenue |
|||||||||
| Subsidiary Revenue Share of Group Revenue % of consolidated revenue |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Jul - Certificate under Regulation 74(5) of the SEBI (Depositaries and Participants) Regulations, 2018 for the quarter ended June 30, 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
30 Jun - Board approved appointment of V Mahendra & Associates as internal auditor for FY 2026-27 on 30 June 2026.
- Closure of Trading Window 26 Jun
-
Announcement under Regulation 30 (LODR)-Change in Management
25 Jun - Dr. Jagadeesh M N resigned as Vice President, Discovery Services, effective June 25, 2026.
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015-Providing Corporate Guarantee To Subsidiary
13 Jun - Company issued Rs55 lakh corporate guarantee for Adita Bio Sys under ECLGS 5.0; no current impact.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview[1]
The company is engaged in research, development, and manufacturing services.
It is pursuing organic and inorganic growth opportunities and is in the process of a business transition, including strengthening its leadership team. It is working towards establishing a Contract Research, Development, and Manufacturing Organization (CRDMO) to offer integrated services across pharma, biopharma, agrochemicals, medical devices, and specialty chemicals for domestic and international markets.